Septerna (NASDAQ:SEPN) Shares Gap Down – Time to Sell?

Shares of Septerna, Inc. (NASDAQ:SEPN) gapped down prior to trading on Monday . The stock had previously closed at $37.34, but opened at $35.18. Septerna shares last traded at $34.9050, with a volume of 136,353 shares changing hands.

Analyst Ratings Changes

Several analysts have issued reports on SEPN shares. Stifel Nicolaus started coverage on Septerna in a research note on Friday, May 1st. They issued a “buy” rating and a $43.00 price objective on the stock. Wells Fargo & Company lifted their target price on Septerna from $28.00 to $48.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 3rd. Guggenheim began coverage on Septerna in a research note on Thursday, June 11th. They issued a “buy” rating and a $52.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $60.00 price target on shares of Septerna in a report on Tuesday, March 10th. Finally, Wall Street Zen downgraded shares of Septerna from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Septerna currently has a consensus rating of “Moderate Buy” and a consensus price target of $45.78.

Septerna Stock Performance

The stock’s 50 day moving average price is $29.24 and its 200 day moving average price is $27.37. The company has a market capitalization of $1.55 billion, a P/E ratio of -42.22 and a beta of 2.39.

Septerna (NASDAQ:SEPN) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.23. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. The company had revenue of $26.52 million during the quarter, compared to analyst estimates of $16.98 million. On average, analysts expect that Septerna, Inc. will post -1.57 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, SVP Daniel D. Long sold 15,000 shares of the stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $35.51, for a total transaction of $532,650.00. Following the transaction, the senior vice president owned 96,412 shares of the company’s stock, valued at approximately $3,423,590.12. This trade represents a 13.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Elizabeth Bhatt sold 4,000 shares of the company’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $24.34, for a total transaction of $97,360.00. Following the sale, the chief operating officer owned 174,209 shares of the company’s stock, valued at approximately $4,240,247.06. The trade was a 2.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 42,983 shares of company stock worth $1,375,607 in the last quarter. 5.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Septerna

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Group One Trading LLC boosted its stake in shares of Septerna by 111.8% during the 4th quarter. Group One Trading LLC now owns 944 shares of the company’s stock worth $26,000 after purchasing an additional 8,955 shares during the period. Global Retirement Partners LLC acquired a new position in shares of Septerna in the 4th quarter valued at $35,000. Russell Investments Group Ltd. acquired a new position in shares of Septerna during the third quarter valued at approximately $36,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Septerna in the fourth quarter valued at about $53,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Septerna in the fourth quarter worth about $61,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.